Cargando…

Informal Care Time and Cost in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer’s Disease: Determinants and Level of Change Observed

INTRODUCTION: We evaluate the association between caregiver (informal) time/cost and illness severity from two recently completed clinical trials of an investigational drug for Alzheimer’s disease (AD). METHODS: Changes from baseline caregiver time were calculated and treatment effects analyzed usin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacey, Loretto, Bobula, Joel, Niecko, Timothy, Leibman, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447549/ https://www.ncbi.nlm.nih.gov/pubmed/27878522 http://dx.doi.org/10.1007/s40120-016-0056-2

Ejemplares similares

Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer’s Disease
por: Yang, Kuen-Cheh, et al.
Publicado: (2016)

Heterogeneity in Cost-Effectiveness Analysis of Vaccination for Mild and Moderate Alzheimer’s Disease
por: Lin, Chung-Hsien, et al.
Publicado: (2019)

Cost-effectiveness analysis of the treatment of mild and moderate Alzheimer’s disease in Brazil
por: da Silva, Luciana R., et al.
Publicado: (2018)

Characteristics of falls in mild and moderate Alzheimer’s disease
por: Kato-Narita, Eliane Mayumi, et al.
Publicado: (2009)

Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study
por: Mehta, Suyog, et al.
Publicado: (2012)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Neuropsychological Rehabilitation in Mild and Moderate Alzheimer’s Disease Patients
por: Ávila, Renata, et al.
Publicado: (2007)

The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease
por: Hartry, Ann, et al.
Publicado: (2018)

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
por: Ritchie, Marina, et al.
Publicado: (2023)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Dysphagia is closely related to frailty in mild-to-moderate Alzheimer’s disease
por: Güner, Merve, et al.
Publicado: (2023)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
por: Lawlor, Brian, et al.
Publicado: (2018)

Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia
por: Hannestad, Jonas, et al.
Publicado: (2020)

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer’s disease
por: Rijpma, Anne, et al.
Publicado: (2015)

Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer’s disease
por: Maynard, Steven Douglas, et al.
Publicado: (2013)

Analysis of word number and content in discourse of patients with mild to moderate Alzheimer's disease
por: de Lira, Juliana Onofre, et al.
Publicado: (2014)

Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial
por: Jia, Yujie, et al.
Publicado: (2017)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

Effect of Integrated Cognitive Intervention Therapy in Patients with Mild to Moderate Alzheimer's Disease
por: Jung, Young Hee, et al.
Publicado: (2020)

Selective impairment of musical emotion recognition in patients with amnesic mild cognitive impairment and mild to moderate Alzheimer disease
por: Zhou, Shan-Shan, et al.
Publicado: (2019)

Health Care Resource Use and Social Costs in Mild Cognitive Impairment and Mild Alzheimer’s Disease
por: Takechi, Hajime, et al.
Publicado: (2023)

Cognitive and Affective Changes in Mild to Moderate Alzheimer’s Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A 6-Month Observational Study
por: Spalletta, Gianfranco, et al.
Publicado: (2014)

The High Direct Medical Costs of Prader-Willi Syndrome
por: Shoffstall, Andrew J., et al.
Publicado: (2016)

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
por: Piette, François, et al.
Publicado: (2011)

Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine
por: Schmidt, R, et al.
Publicado: (2008)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Retrospective cohort study of the efficacy of caprylic triglyceride in patients with mild-to-moderate alzheimer’s disease
por: Maynard, Steven Douglas, et al.
Publicado: (2013)

Can theory of mind deficits be measured reliably in people with mild and moderate Alzheimer’s dementia?
por: Choong, Caroline SM, et al.
Publicado: (2013)

Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials
por: Vandenberghe, Rik, et al.
Publicado: (2016)

Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil
por: Hwang, Tae-Young, et al.
Publicado: (2016)

Evaluation of inner retinal layers as biomarkers in mild cognitive impairment to moderate Alzheimer’s disease
por: Lad, Eleonora M., et al.
Publicado: (2018)

ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease
por: Cummings, Jeffrey L., et al.
Publicado: (2018)

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
por: Landen, Jaren W., et al.
Publicado: (2017)

Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
por: Abushouk, Abdelrahman Ibrahim, et al.
Publicado: (2017)

RELATIONSHIP OF CARDIOPULMONARY EXERCISE TESTING AND FIELD WALKING TESTS IN MILD-MODERATE ALZHEIMER’S DEMENTIA
por: Salisbury, Dereck L, et al.
Publicado: (2019)

Relationships of Fall Risk With Frailty, Sarcopenia, and Balance Disturbances in Mild-to-Moderate Alzheimer’s Disease
por: Güner Oytun, Merve, et al.
Publicado: (2023)

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands
por: Hoogveldt, Bart, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ku5p8tbsingbpa7bl527d6nl9f